Media manufacturing can become a major source of risk as programs move from early development into GMP production, especially when speed, consistency and regulatory readiness must all be maintained. This webinar explores an integrated approach to custom media manufacturing, guiding the transition from non‑GMP development to GMP production.
In media manufacturing, the move to larger-scale production often introduces new risks that can affect timelines, consistency and supply. The featured speaker will cover strategies for de-risking scale-up as programs move from early development to large-scale commercial supply, even under compressed timelines.
Attendees will gain practical insights into aligning non-GMP prototyping with GMP-compliant manufacturing to support regulatory readiness, protect proprietary formulations and maintain long-term supply continuity across global manufacturing sites. Real‑world examples will highlight how integrated manufacturing strategies enhance flexibility and accelerate speed‑to‑market.
Register for this webinar to learn how media manufacturing supports a smoother transition from development to GMP.
Speaker
Albert Cheong, Sales Manager, Korea and Media Development Lab, Lonza Bioscience Singapore
Albert Cheong is currently the Sales Manager, Korea and Media Development Lab for Lonza Bioscience Singapore. For more than 20 years, he has been involved in the biopharma industry, providing effective technical solutions, mainly Upstream Cell Culture Media and Process Development, to a multitude of clients in APAC.
Prior to joining Lonza Bioscience, he was a Senior Scientist at Lonza Biologics Tuas, Singapore, leading a team providing cell line development services to APAC clients using Lonza Biologics GS-Xceed® CHO cell line. He was also an Assoc Tech Director for Media Services and Product Applications APAC at Thermo Fisher Scientific; a Head of MSAT Upstream Asia for SAFC (now Merck KgaA), as well as the Technical Director for a cultivated meat start-up, TurtleTree Labs Pte Ltd, all based in Singapore.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Upstream Process Development Scientists
- Process Development Scientists
- Media Development and Cell Culture Scientists
- Discovery Scientists and Principal Investigators working in early-stage development
- Technology Transfer Leads
- External Manufacturing and CDMO Interface Managers
- MSAT Scientists
- Manufacturing Managers
What You Will Learn
Attendees will gain insight into:
- How integrated media manufacturing reduces risk between non-GMP development and GMP production
- Ways to align non-GMP prototyping with GMP-compliant manufacturing to support regulatory readiness
- Approaches for protecting proprietary formulations and maintaining supply continuity across global sites
- Real-world examples showing how integrated manufacturing strategies improve flexibility and speed to market
Xtalks Partner
Lonza
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), supporting the healthcare industry from early development through commercial manufacturing. We partner with customers ranging from emerging biotechs to global pharmaceutical companies to transform therapeutic discoveries into life‑saving and life‑enhancing treatments.
Founded in 1897 in the Swiss Alps, Lonza brings more than 125 years of innovation and manufacturing expertise. Today, our global network includes approximately 20,000 colleagues across more than 30 sites on five continents. Our business is structured across three synergistic platforms—Integrated Biologics, Advanced Synthesis, and Specialized Modalities—spanning established and emerging technologies such as biologics, small molecules, mRNA, and cell and gene therapies.
United by a common purpose, we deliver integrated solutions that help turn breakthrough science into viable medicines for patients worldwide.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account